Cadrenal Therapeutics Common Stock Alpha and Beta Analysis
| CVKD Stock | 8.22 0.05 0.61% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cadrenal Therapeutics Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cadrenal Therapeutics over a specified time horizon. Remember, high Cadrenal Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cadrenal Therapeutics' market risk premium analysis include:
Beta 1.51 | Alpha (0.64) | Risk 7.23 | Sharpe Ratio (0.08) | Expected Return (0.59) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Cadrenal Therapeutics Backtesting, Cadrenal Therapeutics Valuation, Cadrenal Therapeutics Correlation, Cadrenal Therapeutics Hype Analysis, Cadrenal Therapeutics Volatility, Cadrenal Therapeutics History and analyze Cadrenal Therapeutics Performance. Cadrenal Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cadrenal Therapeutics market risk premium is the additional return an investor will receive from holding Cadrenal Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cadrenal Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cadrenal Therapeutics' performance over market.| α | -0.64 | β | 1.51 |
Cadrenal Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cadrenal Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Cadrenal Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cadrenal Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Cadrenal Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cadrenal Therapeutics shares will generate the highest return on investment. By understating and applying Cadrenal Therapeutics stock market price indicators, traders can identify Cadrenal Therapeutics position entry and exit signals to maximize returns.
Cadrenal Therapeutics Return and Market Media
The median price of Cadrenal Therapeutics for the period between Tue, Oct 14, 2025 and Mon, Jan 12, 2026 is 11.3 with a coefficient of variation of 22.87. The daily time series for the period is distributed with a sample standard deviation of 2.47, arithmetic mean of 10.8, and mean deviation of 2.17. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 1129 shares by Quang Pham of Cadrenal Therapeutics, at 14.03 subject to Rule 16b-3 | 10/24/2025 |
2 | Disposition of 1315 shares by Quang Pham of Cadrenal Therapeutics, at 13.99 subject to Rule 16b-3 | 10/27/2025 |
3 | Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 11/10/2025 |
4 | Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks | 11/18/2025 |
5 | Insider Trading | 11/24/2025 |
6 | Acquisition by Golden Lee Scott of 5000 shares of Cadrenal Therapeutics, at 8.27 subject to Rule 16b-3 | 12/02/2025 |
7 | Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia | 12/11/2025 |
8 | Cadrenals Quiet Expansion Play Is Starting to Get Loud | 12/12/2025 |
9 | Cadrenal Therapeutics announces new securities purchase agreement - MSN | 12/16/2025 |
10 | Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail | 12/24/2025 |
11 | Cadrenals Pipeline Looks Less Like a Microcap and More Like an Emergency Response System | 12/30/2025 |
About Cadrenal Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cadrenal or other stocks. Alpha measures the amount that position in Cadrenal Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Cadrenal Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cadrenal Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cadrenal Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cadrenal Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cadrenal Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cadrenal Therapeutics' management manipulating its earnings.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cadrenal Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cadrenal Therapeutics Backtesting, Cadrenal Therapeutics Valuation, Cadrenal Therapeutics Correlation, Cadrenal Therapeutics Hype Analysis, Cadrenal Therapeutics Volatility, Cadrenal Therapeutics History and analyze Cadrenal Therapeutics Performance. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Cadrenal Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.